Circulating plasma antioxidants, inflammatory markers and asymptomatic carotid atherosclerosis in end-stage renal disease patients: A case control study

International Journal of Immunopathology and Pharmacology

Volumn 23, Issue 1, 2010, Pages 327-334

  Riccioni, Graziano ^a   D'Orazio, N ^b   Scotti, L ^b   Petruzzelli, R ^b   Latino, A ^a   Bucciarelli, V ^b   Pennelli, A ^b   Cicolini, G ^b   Di Ilio, E ^b   Bucciarelli, T ^b  

^a SAN CAMILLO DE LELLIS HOSPITAL   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

Atherosclerosis; Cardiovascular disease; Carotid artery disease; End stage renal disease; Hemodialysis; Intima media thickness; Renal failure

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; BETA CAROTENE; C REACTIVE PROTEIN; FIBRINOGEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYCOPENE; RETINOL;

AGED; ANAMNESIS; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; FOOD INTAKE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LABORATORY TEST; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL;

EID: 77951729986     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201002300131     Document Type: Article

References (49)

1. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N; European Uremic Toxin Work Group. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20:1048-1056
2. Henry RM, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int 2002; 62:1402-1407
3. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000; 356:147-152 (Pubitemid 30438520)
4. Drey N, Roderick P, Mullee M, Rogerson M. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. Am J Kidney Dis 2003; 42:677-684 (Pubitemid 37187367)
5. Zoccali C. Cardiovascular risk in uremic patients - is it fully explained by classical risk factors? Nephrol Dial Transplant 2000; 15:454-457
6. Stenvinkel P, Pecoits-Filho R, Lindholm B. Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol 2003; 14:1927-1939.
7. Ritz E. Atherosclerosis in dialyzed patients. Blood Purif 2004; 22:28-37.
8. Himmelfarb J. Oxidative stress in hemodialysis. Contrib Nephrol 2008; 161:132-137
9. Terawaki H, Yoshimura K, Hasegawa T, et al. Oxidative stress in enhanced in correlation with renal dysfunction: examination with the redox state of albumin. Kidney Int 2004; 66:1988-1993
10. Cohen G, Glorieux G, Thornalley P, et al: European Uremic Toxin Work Group (EUTox). Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro-towards a standardized approach for research on uraemia. Nephrol Dial Transplant 2007; 22: 3381-3390
11. Nickolas TL, Barasch J, Devarajan P. Biomarkers in acute and chronic kidney disease. Curr Opin Nephrol Hypertens 2008; 17:127-132 (Pubitemid 351253035)
12. Perna AF, Capasso R, Acanfora F, Satta E, Lombardi C, Ingrosso D, Violetti E, Romano MM, De Santo NG. Toxic effects of hyperhomocysteinemia in chronic renal failure and in uremia: cardiovascular and metabolic consequences. Semin Nephrol 2006; 26:20-23 (Pubitemid 43075505)
13. Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993; 21:573-592
14. Zanetti M, Barazzoni R, Guarnieri G. Inflammation and insulin resistance in uremia. J Ren Nutr 2008; 18:70-75
15. Cibulka R, Racek J. Metabolic disorders in patients with chronic kidney failure. Physiol Res 2007; 56:697-705.
16. Shoji T, Nishizawa Y, Kawagishi T, Emoto M, Morii H. Secondary hyperparathyroidism, decreased hepatic triglyceride lipase, elevated intermediate density lipoprotein and atherosclerosis in hemodialysis patients. Nephron 1998; 78:121-122
17. Kawagishi T, Nishizawa Y, Konishi T, Kawasaki K, Emoto M, Shoji T, Tabata T, Inoue T, Morii H. High-resolution B-mode ultrasonography in evaluation of atherosclerosis in uremia. Kidney Int 1995; 48:820-6.
18. Shoji T, Kawagishi T, Emoto M. Additive impacts of diabetes and renal failure on carotid atherosclerosis. Atherosclerosis 2008; 153:257-258
19. Zoungas S, Asmar RP. Arterial stiffness and cardiovascular outcome. Clin Exp Pharmacol Physiol 2007; 34:647-651
20. Shoji T, Nishizawa Y, Kawagishi T, Kawasaki K, Taniwaki H, Tabata T, Inoue T, Morii H. Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol 1998; 9:1277-1284 (Pubitemid 28283892)
21. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, Levey AS. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000; 58:353-362 (Pubitemid 30429882)
22. Zima T, Janebová M, Nemecek K, Bártová V. Retinol and alpha-tocopherol in hemodialysis patients. Ren Fail 1998; 20:505-512
23. Gelardi M, Maselli del Giudice A, Fiorella ML, Soleti P, Di Gioacchino M, Conti CM, Fulcheri M, Doyle R, Ciprandi G. Quality of life in non-allergic rhinitis depends on the predominant inflammatory cell type. J Biol Regul Homeost Agents 2008; 22:73-81. (Pubitemid 351577895)
24. Boaz M, Iuliano L, Himmelfarb J, et al. Baseline oxysterols and other markers of oxidative stress, inflammation and malnutrition in the vitamin E and intima media thickness progression in end-stage renal disease (VIPER) cohort. Nephron Clin Pract 2005; 100:111-119 (Pubitemid 40910987)
25. Sodin-Semrl S, Antico G, Mikus R, Lakota K, Varga J, Fiore S. Lipoxin A and serum amyloid A differentially modulate phospholipase D in human fibroblast-like synoviocytes. Eur J Inflamm 2009; 7:9-18.
26. Usberti M, Gerardi GM, Gazzotti RM, et al. Oxidative stress and cardiovascular disease in dialyzed patients. Nephron 2002; 91:25-33. (Pubitemid 34522829)
27. Hodkova M, Dusilova-Sulkova S, Kalousova M, Uhrová J, Tesar V, Zima T. Influence of oral vitamin E therapy on micro-inflammation and cardiovascular disease markers in chronic hemodialysis patients. Ren Fail 2006; 28:395-399
28. Chiorino G, Mello Grand M, Scatolini M, Ostano P. From single gene to integrative molecular concept MAPS: pitfalls and potentials of microarray technology. J Biol Regul Homeost Agents 2008; 22:7-16.
29. Brzosko S, Lebkowska U, Malyszko J, Hryszko T, Krauze-Brzosko K, Mysliwiec M. Intima media thickness of common carotid arteries is associated with traditional risk factors and presence of ischaemic heart disease in hemodialysis patients. Physiol Res 2005; 54:497-504.
30. Rollino C, Massara C, Besso L, et al. Carotid intima-media thickness and anti-phospholipid antibodies in patients with systemic lupus erythematosus. Eur J Inflamm 2009; 7:19-24.
31. Shoji T, Emoto M, Tabata T, et al. Advanced atherosclerosis in pre-dialysis patients with chronic renal failure. Kidney International 2002; 61:2187-92.
32. Rogers M-L, Beare A, Zola H, Rush RA. CD 271 (P75 neurotrophin receptor). J Biol Regul Homeost Agents 2008; 22:1-6.
33. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999;55:648-658
34. Papadopoulos PC, Kotridis P, Kokkas B, et al. Carvedilol increases atrial natriuretic peptide plasma levels in hypertensive patients. Eur J Inflamm 2007; 5:97-101.
35. Kanters SD, Algra A, van Leeuwen MS, Banga JD. Reproducibility of in vivo carotid intima-media thickness measurements. Stroke 1997; 28: 665-671 (Pubitemid 27118395)
36. Howard G, Sharrett AR, Heiss G, Evans GW, Chambless LE, Riley WA, Burke GL. Carotid artery intimal-medial thickness distribution in general populations as evaluated by B-mode ultrasound. Stroke 1993; 24:1297-1304
37. Crouse JR III, Byngton RP, Bond MG. Pravastatin, lipids and atherosclerosis in the carotid arteries (PLAC II). Am J Cardiol 1995; 75:455-459
38. Lee BL, Chua SC, Ong HY. High-performance liquid chromatographic method for routine determination of vitamins A and E and β-carotene. J Chromatogr 1999; 581:41-47
39. Kim S-J, Ramesh C, Gupta H, Lee W. Taurine-Diabetes Interaction: from involvement to protection. J Biol Regul Homeost Agents 2007; 21:63-77.
40. Sakurabayashi T, Fujimoto M, Takaesu Y, et al. Association between plasma homocysteine concentration and carotid atherosclerosis in hemodialysis patients. Jpn Circ J 1999; 63:692-696
41. Guz G, Nurhan Ozdemir F, Sezer S, Sezer S, Işiklar I, Arat Z, Turan M, Haberal M. Effect of apolipoprotein E polymorphism on serum lipid, lipoproteins, and atherosclerosis in hemodialysis patients. Am J Kidney Dis 2000; 36:826-836
42. Hojs R. Carotid intima-media thickness and plaques in hemodialysis patients. Artif Organs 2000; 24:691-695
43. Lakota K, Mrak-Poljšak K, Rozman B, Kveder T, Tomšič M, Sodin-Semrl S. Serum amyloid A activation of inflammatory and adhesion molecules in human coronary artery and umbilical vein endothelial cells. Eur J Inflamm 2007; 5:73-81.
44. Uzun H, Konukoglu D, Besler M, Müderrisoglu C, Aydin S. The effects of renal replacement therapy on plasma, asymmetric dimethylarginine, nitric oxide and C-reactive protein levels. Clin Invest Med 2008; 31:1-7.
45. Himmelfarb J, Phinney S, Ikizler TA, Kane J, McMonagle E, Miller G. Gamma-tocopherol and docosahexaenoic acid decrease inflammation in dialysis patients. J Ren Nutr 2007; 17:296-304.
46. Deviri E, Glenville BE. Inflammatory response in infective endocarditis. Eur J Inflamm 2007; 5:57-63.
47. Goodship TH. Fibrinogen in hemodialysis: the worst of both worlds? Kidney Int 2003; 63:379-380
48. Katsanos GS, Anogeianaki A, Orso C, Tetè S, Salini V, Antinolfi PL, Sabatino G. Mast cells and chemokines. J Biol Regul Homeost Agents 2008; 22:145-151
49. Riccioni G, De Santis A, Cerasa V, Menna V, Di Hio C, Ballone E, D'Orazio N. Atherosclerotic plaque formation and risk factors. Int J Immunopathol Pharmacol 2003; 16:25-31.